United Kingdom-based AstraZeneca has started a phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine intended to decrease blood cholesterol levels in patients with dyslipidemia, it was reported on Monday.
The product is a LIgand Conjugated Antisense medicine being developed in collaboration with United States-based Ionis Pharmaceuticals Inc. It targets proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol.
The Phase 2b, randomised, double-blind, placebo-controlled trial is enrolling around 108 participants between the age of 18 to 75 years, who have low-density lipoprotein cholesterol levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association guidelines on blood cholesterol management. The main aim is to evaluate the effect of different doses of the product on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy. The study is to assess three dose levels of the product compared to the placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder